Tennessee House Bill HB2101

Tennessee 2025-2026 Regular Session

• Introduced: 2/2/26
• Refer: 2/5/26
• Refer: 3/18/26
• Refer: 3/25/26
• Refer: 3/31/26
• Engrossed: 4/6/26
• Enrolled: 4/10/26
• Passed: 4/27/26
• Chaptered: 5/5/26

Caption

AN ACT to amend Tennessee Code Annotated, Title 39, Chapter 17, Part 4, relative to drugs.

Summary

HB2101 revises Tennessee’s laws governing the sale and tracking of pseudoephedrine and ephedrine products, which are methamphetamine precursors. The bill updates terminology throughout the statute to refer to an “electronic sales tracking system” rather than NPLEx, and it clarifies that the system is used to record and monitor real-time purchases to prevent or investigate illegal purchases. It also expands the statute to expressly cover pharmacist-generated prescription orders and defines the administrator responsible for the tracking system. The bill requires pharmacies to use the electronic tracking system for covered over-the-counter sales, submit transactions before completing a sale, correct data-entry errors, and comply with stop-sale alerts. It preserves an immunity provision for pharmacies that follow the law absent negligence or misconduct, limits use of the data to law enforcement, healthcare professionals, and pharmacists, and provides a fallback to the Tennessee Methamphetamine Information System if the current system is unavailable. It also adds rules for online and remote sales, including government-issued ID verification, address confirmation, pre-sale tracking-system checks, and delivery only to the purchaser’s residential address. Finally, beginning in 2027, manufacturers of ephedrine or pseudoephedrine products sold in Tennessee must pay monthly fees to support the system, with annual fee increases capped unless justified by cost increases. The bill’s impact is primarily on Tennessee Code Annotated Title 39, Chapter 17, Part 4, by modernizing and expanding the state’s pseudoephedrine control framework. It affects pharmacies, pharmacists, pharmacy interns, manufacturers, online sellers, and purchasers of methamphetamine precursor products, while also involving the Tennessee Bureau of Investigation and the tracking-system administrator. The act takes effect July 1, 2026. The overall sentiment appears strongly favorable and noncontroversial. The bill advanced through subcommittee and committee stages with unanimous votes and passed the House floor overwhelmingly, indicating broad support for tighter controls on methamphetamine precursor sales and for updating the state’s tracking infrastructure. The committee history suggests the measure was viewed as a technical and public-safety-oriented update rather than a contested policy change. The main points of emphasis are operational rather than ideological. Support appears centered on preventing methamphetamine diversion, improving real-time tracking, and extending controls to remote sales. Potential concerns addressed in the bill include pharmacy liability, data-use restrictions, and the cost of maintaining the tracking system, which the bill shifts in part to manufacturers starting in 2027. No recorded opposition appears in the provided voting history.

Impact

HB2101 amends Tennessee Code Annotated § 39-17-431 and related provisions governing pseudoephedrine and ephedrine sales. It replaces references to NPLEx and NADDI with the broader term “electronic sales tracking system,” adds definitions, imposes new requirements for online and remote sales, and establishes a manufacturer fee structure beginning in 2027. The bill affects pharmacies, sellers, manufacturers, the TBI, and the system administrator, while preserving existing purchase limits and stop-sale enforcement for methamphetamine precursor products.

Sentiment

The bill appears to have received broad, bipartisan support and moved through the legislative process without recorded opposition in the provided history. Committee recommendations were unanimous, and the House floor vote was overwhelmingly in favor, suggesting the measure was viewed as a practical public-safety and administrative update to Tennessee’s drug-control laws.

Contention

There is little evidence of substantive controversy in the available materials. The only notable issues reflected in the bill text are operational concerns: pharmacy compliance with the electronic tracking system, liability protections for pharmacies, privacy limits on data use, and the new manufacturer fee requirement. The bill also extends controls to online and remote sales, which could be a point of concern for sellers, but no opposition is shown in the votes or context provided.